Search results
Showing 136 to 150 of 318 results for breast cancer
Awaiting development Reference number: GID-TA10960 Expected publication date: TBC
Following the government’s 10 Year Health Plan for England, we're strengthening our role in getting the best healthtech, including digital tools, diagnostics and medical devices, to patients.
Discontinued Reference number: GID-TAG404
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.
Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating relapsing–remitting multiple sclerosis in adults.
This quality standard covers providing and organising services for people with sarcoma. It includes pathways for referral and diagnosis, treatment and support for adults, young people and children with sarcoma. It describes high-quality care in priority areas for improvement.
View quality statements for QS78Show all sections
Sections for QS78
- Quality statements
- Quality statement 1: Diagnostic pathways
- Quality statement 2: Multidisciplinary teams for sarcoma
- Quality statement 3: Publishing information about areas of expertise
- Quality statement 4: Retroperitoneal sarcoma
- Quality statement 5: Surgical skills
- Quality statement 6: Key workers
- Update information
Studies show that risk-reducing surgery significantly reduces risk of breast cancer, but there is insufficient evidence to decide...
Awaiting development Reference number: GID-TA11535 Expected publication date: TBC
of mutations and need adjustment for pathological subtypes of breast and ovarian cancer, which are particularly associated...
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
Discontinued Reference number: GID-TAG403
for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer? Any explanatory notes(if applicable) To find out why...
In development Reference number: GID-TA10326 Expected publication date: TBC
Awaiting development Reference number: GID-TA11769 Expected publication date: TBC
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.
Etirinotecan pegol for treating breast cancer with brain metastases [ID881]
Discontinued Reference number: GID-TA10066